Patients and Treatment
Between August 30, 2017 and June 9, 2020, 57 of the 88 screened patients were enrolled (33 patients in the dose-escalation period and 24 in the dose-expansion period) (Demographic and baseline characteristics of all patients (dose-escalation and dose-expansion periods)


Abbreviations: BID, twice daily; BRCA, Patient disposition. As of June 9, 2020, nine (15.8%) patients were still on trial (4 in the 50-mg BID group in the dose-escalation period and 5 in the 100-mg group in the dose-expansion period) (